A multi-protein biomarker blood test for organ confined prostate cancer

OCProDx has the ability to meet important end-user needs – both for the patient and the physician. Using a patient’s blood sample the test uses Multiple Reaction Monitoring (MRM) to measure the levels of a set of proteins in the blood which indicate if a prostate tumour has extended beyond the prostate or remains confined. Our expert team analyses this information to provide a confinement score. This is of huge benefit to men diagnosed with prostate cancer as it provides information to guide significant life changing decisions they will have to make about their treatment, all without the need for invasive surgery. Atturos plan to make the OCProDx test available by mid 2021.